CEO Albert Bourla told investors Tuesday morning that he is “cautiously optimistic” about working with Robert F. Kennedy Jr., ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He admitted that after the company made a “big miscalculation” around ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

Pfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January by chief operating officer Albert Bourla. In contrast to Merck & Co. which has rescinded a company ...

Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.

Pfizer (PFE) CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the investor disclosed a stake in the company and ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...